Search details
1.
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Cell
; 171(2): 481-494.e15, 2017 Oct 05.
Article
in English
| MEDLINE | ID: mdl-28985567
2.
The whole-genome landscape of Burkitt lymphoma subtypes.
Blood
; 134(19): 1598-1607, 2019 11 07.
Article
in English
| MEDLINE | ID: mdl-31558468
3.
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Blood
; 128(26): 3083-3100, 2016 12 29.
Article
in English
| MEDLINE | ID: mdl-27760757
4.
Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.
Blood
; 125(10): 1589-600, 2015 Mar 05.
Article
in English
| MEDLINE | ID: mdl-25612622
5.
Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia.
Blood
; 123(16): 2518-29, 2014 Apr 17.
Article
in English
| MEDLINE | ID: mdl-24591202
6.
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Mod Pathol
; 28(12): 1555-73, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26541272
7.
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
Mod Pathol
; 28(10): 1297-314, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26248897
8.
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Mod Pathol
; 28(9): 1202-13, 2015 Sep.
Article
in English
| MEDLINE | ID: mdl-26111978
9.
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Blood
; 122(15): 2630-40, 2013 Oct 10.
Article
in English
| MEDLINE | ID: mdl-23982177
10.
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Blood
; 121(22): 4529-40, 2013 May 30.
Article
in English
| MEDLINE | ID: mdl-23515929
11.
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Blood
; 121(14): 2715-24, 2013 Apr 04.
Article
in English
| MEDLINE | ID: mdl-23343832
12.
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Blood
; 121(20): 4021-31; quiz 4250, 2013 May 16.
Article
in English
| MEDLINE | ID: mdl-23449635
13.
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Mod Pathol
; 27(7): 958-71, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24336156
14.
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Blood
; 119(22): 5133-43, 2012 May 31.
Article
in English
| MEDLINE | ID: mdl-22368270
15.
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Blood
; 120(19): 3986-96, 2012 Nov 08.
Article
in English
| MEDLINE | ID: mdl-22955915
16.
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Haematologica
; 98(2): 255-63, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-22929980
17.
CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation.
Blood
; 115(12): 2458-61, 2010 Mar 25.
Article
in English
| MEDLINE | ID: mdl-20093404
18.
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.
Blood
; 116(23): e118-27, 2010 Dec 02.
Article
in English
| MEDLINE | ID: mdl-20733160
19.
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Haematologica
; 100(7): e250-3, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25820334
20.
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
J Hematol Oncol
; 13(1): 148, 2020 11 04.
Article
in English
| MEDLINE | ID: mdl-33148342